tiprankstipranks
Centessa Pharmaceuticals Advances Pipeline with Promising OX2R Data
Company Announcements

Centessa Pharmaceuticals Advances Pipeline with Promising OX2R Data

Don't Miss our Black Friday Offers:

Centessa Pharmaceuticals ( (CNTA) ) has shared an update.

Centessa Pharmaceuticals is making strides with its OX2R agonist program, showcasing promising interim data for ORX750 in treating sleep disorders like narcolepsy and hypersomnia. The company is advancing its pipeline with Phase 2a studies and new candidates like ORX142 and ORX489, while reallocating resources from discontinued projects like SerpinPC. With a strong financial position, Centessa is poised to drive innovation and address unmet needs in the neurological and psychiatric treatment landscape.

For a thorough assessment of CNTA stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyCentessa price target raised to $28 from $24 at Guggenheim
TheFlyAlkermes price target raised to $31 from $28 at BofA
TipRanks Auto-Generated NewsdeskCentessa Pharmaceuticals Strengthens Financial Position Amid Losses
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App